Compare HELP & ETW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HELP | ETW |
|---|---|---|
| Founded | 2019 | N/A |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.2M | 1.0B |
| IPO Year | 2020 | 2005 |
| Metric | HELP | ETW |
|---|---|---|
| Price | $10.50 | $9.33 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $41.54 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 228.6K |
| Earning Date | 11-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.76 | $8.46 |
| 52 Week High | $15.15 | $9.95 |
| Indicator | HELP | ETW |
|---|---|---|
| Relative Strength Index (RSI) | 44.49 | 40.80 |
| Support Level | $9.97 | $9.23 |
| Resistance Level | $11.74 | $9.54 |
| Average True Range (ATR) | 0.83 | 0.11 |
| MACD | 0.04 | 0.00 |
| Stochastic Oscillator | 42.61 | 10.20 |
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Eaton Vance Tax-mangd Glo Buy-write Oppo is a United States-based diversified, closed-end management investment company. The primary investment objective of the company is to provide current income and gains. The secondary objective of the fund is capital appreciation. The fund invests in a diversified portfolio of common stocks and writes call options on one or more U.S. indices on a substantial portion of the value of its common stock portfolio to generate current earnings from the option premium. Its portfolio of investments consists of capital markets, chemicals, banks, biotechnology, media, and other sectors.